Key facts
- InBrain Pharma’s last known valuation is $3.5M (Dec 2018).
- It has raised $6.6M.
- Notable investors include Eurasanté, Finovam Gestion, Fondation de l'Université de Lille, France Parkinson, Nord France Amorçage.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for InBrain Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for InBrain Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InBrain Pharma
Developer of a brain infusion technology designed to treat neurodegenerative diseases with technological advancement. The company's technology allows precise, continuous, and targeted administration of drugs inside the central nervous system, increasing the efficiency and the safety of the treatments, enabling healthcare professionals to treat neurodegenerative diseases properly.
- Sector
- Healthcare
- HQ
- Loos, France
- Founded
- 2017
- Employees
- 9
- Website
- inbrainpharma.com/
- Ownership
- Privately Held (backing)
InBrain Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InBrain Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InBrain Pharma in its N-PORT filings yet. We sweep new filings monthly.